{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:34:28Z","timestamp":1790573668814,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1124\/dmd.110.034009","type":"journal-article","created":{"date-parts":[[2010,5,18]],"date-time":"2010-05-18T03:04:34Z","timestamp":1274151874000},"page":"1381-1391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics"],"prefix":"10.1016","volume":"38","author":[{"given":"R. Scott","family":"Obach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim F.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.110.034009_bib1","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1124\/dmd.107.017095","article-title":"Use of isolated hepatocyte preparations for cytochrome P450 inhibition studies: comparison with microsomes for Ki determination","volume":"35","author":"Brown","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.034009_bib2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0006-2952(97)00100-7","article-title":"Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A","volume":"53","author":"Chiba","year":"1997","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.110.034009_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1067\/mcp.2002.121788","article-title":"Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19)","volume":"71","author":"Christensen","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.034009_bib4","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","article-title":"Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction","volume":"75","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.034009_bib5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/138920008786485164","article-title":"Methods for predicting in vivo pharmacokinetics using data from in vitro assays","volume":"9","author":"Houston","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.110.034009_bib6","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0091270007312153","article-title":"New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process","volume":"48","author":"Huang","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.110.034009_bib7","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1124\/dmd.106.014613","article-title":"Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5)","volume":"35","author":"Jones","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.034009_bib8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/0091270005283461","article-title":"Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia","volume":"46","author":"Karim","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.110.034009_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF00194397","article-title":"Effect of fluconazole on theophylline disposition in humans","volume":"46","author":"Konishi","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.110.034009_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s002280050548","article-title":"The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone","volume":"54","author":"Lamberg","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/dmd.110.034009_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1472-8206.1988.tb00645.x","article-title":"Application of theophylline metabolite assays to the exploration of liver microsome oxidative function in man","volume":"2","author":"Naline","year":"1988","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1124\/dmd.110.034009_bib12","first-page":"81","article-title":"Predicting drug-drug interactions from in vitro drug metabolism data: challenges and recent advances","volume":"12","author":"Obach","year":"2009","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1124\/dmd.110.034009_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.105.093229","article-title":"The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions","volume":"316","author":"Obach","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.110.034009_bib14","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clpt.2005.09.004","article-title":"In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach","volume":"78","author":"Obach","year":"2005","journal-title":"Clin. Pharmacol Ther"},{"key":"10.1124\/dmd.110.034009_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.clpt.2006.01.012","article-title":"Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine","volume":"79","author":"Orlando","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.034009_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2125.2007.02964.x","article-title":"Time-dependent inhibition of human drug metabolizing cytochromes P450 by tricyclic antidepressants","volume":"65","author":"Polasek","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.110.034009_bib17","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/00498250310001646353","article-title":"Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors","volume":"34","author":"Proctor","year":"2004","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.110.034009_bib18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/00007691-199702000-00010","article-title":"Griseofulvin and fluvoxamine interactions with the metabolism of theophylline","volume":"19","author":"Rasmussen","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.110.034009_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/BF01059791","article-title":"Kinetics of drug-drug interactions","volume":"1","author":"Rowland","year":"1973","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.110.034009_bib20","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2165\/00003495-200868130-00011","article-title":"Ramelteon: a review of its use in insomnia","volume":"68","author":"Simpson","year":"2008","journal-title":"Drugs"},{"key":"10.1124\/dmd.110.034009_bib21","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1124\/dmd.32.6.647","article-title":"Validated assays for human cytochrome P450 activities","volume":"32","author":"Walsky","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.034009_bib22","first-page":"415","article-title":"Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2","volume":"70","author":"Yao","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.034009_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1177\/0091270004269015","article-title":"Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes","volume":"44","author":"Yasui-Furukori","year":"2004","journal-title":"J Clin Pharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.110.034009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:51:00Z","timestamp":1739897460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624024401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0090955624024401"],"URL":"https:\/\/doi.org\/10.1124\/dmd.110.034009","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.110.034009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}